(123 days)
Not Found
No
The document explicitly states "Mentions AI, DNN, or ML: Not Found" and the description focuses on established mapping and location technologies.
No.
The device is described as a "catheter-based atrial and ventricular mapping system" that provides "information about the electrical activity of the heart and about catheter location during the procedure" to create "3D anatomical and electroanatomical maps." This functionality is for diagnosis and guidance, not for treating a disease or condition.
Yes
The system provides information about the electrical activity of the heart and creates 3D anatomical and electroanatomical maps based on acquired data points, which are used to display information relevant to diagnosing cardiac electrophysiological conditions.
No
The device description explicitly lists multiple hardware components, including a Patient Interface Unit, Graphic User Interface, monitors, keyboard, mouse, ports, power supply, connection box, cables, pedals, and a location pad.
Based on the provided information, the CARTO® 3 System is not an In Vitro Diagnostic (IVD) device.
Here's why:
- Intended Use: The intended use clearly states "catheter-based cardiac electrophysiological (EP) procedures." This involves directly interacting with the patient's heart in vivo to gather electrical activity and location information.
- Device Description: The description details a system that uses catheters and reference devices to acquire intracardiac signals and display 3D maps of the heart. This is an in vivo process.
- Lack of In Vitro Activities: There is no mention of the device being used to examine specimens (like blood, tissue, or urine) outside of the body, which is the defining characteristic of an IVD.
IVD devices are used to examine specimens obtained from the human body to provide information for diagnostic purposes. The CARTO® 3 System is used during a medical procedure on a living patient.
N/A
Intended Use / Indications for Use
The intended use of the CARTO® 3 System is catheter-based cardiac electrophysiological (EP) procedures. The CARTO 3 System provides information about the electrical activity of the heart and about catheter location during the procedure. The system can be used on patients who are eligible for a conventional electrophysiological procedure. The system has no special contraindications.
Product codes (comma separated list FDA assigned to the subject device)
DQK
Device Description
The CARTO® 3 EP Navigation System, Version 6.0 is a catheter based atrial and ventricular mapping system designed to acquire and analyze data points, and use this information to display 3D anatomical and electroanatomical maps of the human heart. The location information needed to create the cardiac maps and the local electrograms are acquired using a specialized mapping catheters and reference devices. The system allows electrograms and cardiac maps display based on the received intracardiac signals from the catheters. The CARTO® 3 System V6.0 uses two distinct types of location technology – magnetic sensor technology and Advanced Catheter Location (ACL) technology.
The CARTO® 3 System V6.0 consists of the following components:
Patient Interface Unit (PIU) Graphic User Interface (GUI) Wide-Screen monitors, keyboard, and mouse Intracardiac In Port Intracardiac Out Port Power Supply Patches Connection Box and Cables Pedals Location Pad
All hardware components of the CARTO® 3 System V6.0with the VISITAG SURPOINT™ Module are identical to those described for the predicate device.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
human heart
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
The CARTO® 3 EP Navigation System, Version 6.0 with the VISITAG SURPOINT™ Module underwent extensive bench testing to verify the new and modified features and to demonstrate with regression testing that these modifications did not negatively affect existing features. All testing passed in accordance with appropriate test criteria and standards, and the modified device did not raise new questions of safety or effectiveness.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 870.1425 Programmable diagnostic computer.
(a)
Identification. A programmable diagnostic computer is a device that can be programmed to compute various physiologic or blood flow parameters based on the output from one or more electrodes, transducers, or measuring devices; this device includes any associated commercially supplied programs.(b)
Classification. Class II (performance standards).
0
Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which consists of the letters "FDA" in a blue square, followed by the words "U.S. FOOD & DRUG ADMINISTRATION" in blue text.
June 1, 2018
Biosense Webster, Inc. Phuong Chau Senior Regulatory Affairs Program Lead 33 Technology Drive Irvine, CA 92618
Re: K180238
Trade/Device Name: CARTO 3 EP Navigation System Version 6.0 and Accessories Regulation Number: 21 CFR 870.1425 Regulation Name: Programmable Diagnostic Computer Regulatory Class: Class II Product Code: DOK Dated: May 24, 2018 Received: May 25, 2018
Dear Phuong Chau:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820);
1
and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm.
For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely.
M.A. Hilleheme
for Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K180238
Device Name
CARTO 3 EP Navigation System Version 6.0 and Accessories
Indications for Use (Describe)
The intended use of the CARTO® 3 System is catheter-based cardiac electrophysiological (EP) procedures. The CARTO 3 System provides information about the electrical activity of the heart and about catheter location during the procedure. The system can be used on patients who are eligible for a conventional electrophysiological procedure. The system has no special contraindications.
| Type of Use (Select one or both, as applicable) | |
|---|---|
| Prescription Use (Part 21 CFR 801 Subpart D) | Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
510(k) Summary
| Applicant: | Biosense Webster, Inc.
33 Technology Drive
Irvine, CA 92618, USA
Tel.: (800) 729-9010
Fax: (909) 839-8500 |
|---------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Contact Person: | Phuong Chau
Senior Regulatory Affairs Program Lead
Phone: 949-923-4238
Fax: 949-450-6886 |
| Authored by: | Anna Gantman
Quality and Regulatory Program Manager
Biosense Webster (Israel), Ltd.
And
Phuong Chau
Senior Regulatory Affairs Program Lead
Biosense Webster, Inc. |
| Date: | April 10, 2018 |
| Device Trade Name: | CARTO® 3 EP Navigation System Version 6.0 and Accessories |
| Device Common Name: | Cardiac Mapping System |
| Manufacturing Number: | FG-5400-00 |
| Device Classification: | Programmable diagnostic computer
Class II, 21 CFR 870.1425 |
| Product Code | DQK |
| Predicate Device: | CARTO® 3 EP Navigation System Version 6.0 and Accessories
510(k)#: K170600 |
| Manufacturing Facilities: | Biosense Webster (Israel), Ltd.
a Johnson & Johnson Company
4 Hatnufa Street
Yokneam, ISRAEL 2066717
Biosense Webster, Inc.
15715 Arrow Hwy
Irwindale, CA 91706 |
4
| Device Description: | The CARTO® 3 EP Navigation System, Version 6.0 is a catheter based atrial and ventricular mapping system designed to acquire and analyze data points, and use this information to display 3D anatomical and electroanatomical maps of the human heart. The location information needed to create the cardiac maps and the local electrograms are acquired using a specialized mapping catheters and reference devices. The system allows electrograms and cardiac maps display based on the received intracardiac signals from the catheters. The CARTO® 3 System V6.0 uses two distinct types of location technology – magnetic sensor technology and Advanced Catheter Location (ACL) technology. |
|---|---|
| The CARTO® 3 System V6.0 consists of the following components: | |
| Patient Interface Unit (PIU) Graphic User Interface (GUI) Wide-Screen monitors, keyboard, and mouse Intracardiac In Port Intracardiac Out Port Power Supply Patches Connection Box and Cables Pedals Location Pad | |
| All hardware components of the CARTO® 3 System V6.0with the VISITAG SURPOINT™ Module are identical to those described for the predicate device. | |
| Indications for Use: | The intended use of the CARTO® 3 System is catheter-based cardiac electrophysiological (EP) procedures. The CARTO® 3 System provides information about the electrical activity of the heart and about catheter location during the procedure. The system can be used on patients who are eligible for a conventional electrophysiological procedure. The system has no special contraindications. |
| Technological Characteristics: | The modified CARTO® 3 EP Navigation System, Version 6.0 with VISITAG SURPOINT™ Module, has the same technological characteristics (i. e., design, material, chemical composition, energy source) as the predicate CARTO® 3 EP Navigation System, Version 6.0. A summary of the technological characteristics of the new device compared to the predicate device is as follows: Have identical intended use. |
| Have the same hardware platform. Have identical magnetic location mapping technology. Have identical magnetic location sensor accuracy. | |
| The main difference between the predicate device and the | |
| modified device is the enhancement of the VISITAG Module to | |
| add the VISITAG SURPOINT™ Module. The module is used to | |
| display Tag Index calculations performed by the VISITAG | |
| SURPOINT™ EPU device. Additionally, an HD Coloring | |
| feature was implemented to provide high definition coloring of | |
| electroanatomical maps. The HD coloring feature includes the | |
| following GUI enhancements: Cleaner map visualization, | |
| Enhanced wave propagation display, Enhanced visualization of | |
| projected points and Enhancements for the Early Meets Late | |
| mechanism. | |
| Performance Data: | The CARTO® 3 EP Navigation System, Version 6.0 with the |
| VISITAG SURPOINT™ Module underwent extensive bench | |
| testing to verify the new and modified features and to | |
| demonstrate with regression testing that these modifications did | |
| not negatively affect existing features. All testing passed in | |
| accordance with appropriate test criteria and standards, and the | |
| modified device did not raise new questions of safety or | |
| effectiveness. | |
| Conclusions: | The CARTO® 3 EP Navigation System, Version 6.0 and |
| Accessories with the VISITAG SURPOINT™ Module is | |
| substantially equivalent to the currently cleared CARTO® 3 EP | |
| Navigation System, Version 6.0 based on the completion of non- | |
| clinical bench testing and pre-clinical testing as well as similar | |
| principles of design, operation and indications for use. |
- Use the same fundamental scientific technology. ●
5